

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DC0270US.NP

Inventors: Stanton et al.

Serial No.: 10/575,577

Filing Date: Not Yet Assigned

Examiner: Not Yet Assigned

Customer No.: 26259


Group Art Unit: Not Yet Assigned

Confirmation No.: Not Yet Assigned

Title: Modulators of the ABC Transporter Family  
and Methods for Their Use

I, Kathleen A. Tyrrell, Registration No. 38,350,  
certify that this correspondence is being deposited  
with the U.S. Postal Service as First Class mail in  
an envelope addressed to the Commissioner for Patents  
P.O. Box 1450, Alexandria, VA 22313-1450

On this date: June 15, 2006

  
\_\_\_\_\_  
Kathleen A. Tyrrell Registration No. 38,350

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R.  
§§1.97-1.98, information relating to the above-identified  
application is hereby disclosed. Inclusion of information in  
this statement is not to be construed as an admission that this  
information is material as that term is defined in 37 C.F.R.  
§1.56(b).


- (xx) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.
- ( ) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
- ( ) Certification in Accordance with §1.97(e) is attached hereto; or
- ( ) Authorization to charge Deposit Account No. 50-1619 the fee of \$180.00 as set forth in §1.17(p) is provided.
- ( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I)(1).
- (xx) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

( ) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. \_\_\_\_\_, filed \_\_\_\_\_, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

- ( ) The relevance of the listed references in a foreign language is as stated in the specification at pages @@.
- (xx) All listed references are in the English language.

Respectfully submitted,

  
Kathleen A. Tyrrell  
Registration No. 38 | 350

Date: June 15, 2006

Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, New Jersey 08053

(856) 810-1515



Sheet 01 of 04

Form 149 Modified U.S. Patent and Trademark Office		Docket No. <b>DC0270US.NP</b>	Serial No. <b>10/575,577</b>
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>Stanton et al.</b>	
U.S. Department of Commerce		Filing Date <b>Not Yet Assigned</b>	Group <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	AA	Al-Awqati, Qais, "Alternative treatment for secretory diarrhea revealed in a new class of CFTR inhibitors", The Journal of Clinical Investigation 2002 110(11):1599-1601	
	AB	Arceci, Robert J., "Clinical Significance of P-Glycoprotein in Multidrug Resistance Malignancies, Blood 1993 81(9):2215-2222	
	AC	Biedler, June L., "Drug Resistance:Genotype versus Phenotype-Thirty-second G.H. A. Clowes Memorial Award Lecture", Cancer Research 1994 54:666-678	
	AD	Broxterman et al., "Multidrug resistance proteins and other drug transport-related resistance to natural product agents", Current Opinion in Oncology 1995 7:532-540	
	AE	Cole et al., "Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line", Science 1992 258:1650-1654	
	AF	Dalton et al., "The Multidrug-Resistance Gene ( <i>MDR1</i> ) Represents A Potential Target For Reversing Drug Resistance In Human Malignancies", J. NIH Res. 1994 6:54-58	
	AG	Demolombe et al., "ATP-binding cassette proteins as targets for drug discovery", TIPS 1996 17:273-275	
	AH	Fojo et al., "Expression of a multidrug-resistance gene in human tumors and tissues", Proc. Natl. Acad. Sci. USA 1987 84:265-269	
	AI	Gregorcyk et al., "p-Glycoprotein Expression as a Predictor of Breast Cancer Recurrence", Annals of Surgical Oncology 1996 3(1):8-14	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>	Docket No. <b>DC0270US.NP</b>	Serial No. <b>10/575,577</b>
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)	Applicant <b>Stanton et al.</b>	
U.S. Department of Commerce	Filing Date <b>Not Yet Assigned</b>	Group <b>Not Yet Assigned</b>

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

AJ	Hamilton et al., "Differential Effects of Chromium (VI) on Constitutive and Inducible Gene Expression in Chick Embryo Liver In Vivo and Correlation With Chromium (VI)-Induced DNA damage", Molecular Carcinogenesis 1989 2:274-286
AK	Ihnat et al., "Suppression of P-Glycoprotein Expression and Multidrug Resistance by DNA Cross-Linking Agents", Clinical Cancer Research 1997 3:1339-1346
AL	Kerbel et al., "Multicellular Resistance:A New Paradigm to Explain Aspects of Acquired Drug Resistance of Solid Tumors", Cold Spring Harbor Symp. Quant. Biol. 1994 59:661-672
AM	Koh et al., "The Value of Immunohistochemical Detection of P-Glycoprotein in Breast Cancer Before and After Induction Chemotherapy", Yonsei Medical Journal 1992 33(2):137-142
AN	Kunzelmann et al., "Electrolyte Transport in the Mammalian Colon:Mechanisms and Implications for Disease", Physiol. Rev. 2002 82:245-289
AO	List, A.F., "Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia", Leukemia 1996 10:937-942
AP	McCaffrey et al., "Effects of the Genotoxic Carcinogen Chromium (VI) on Basal and Hormone-Inducible Phosphoenolpyruvate Carboxykinase Gene Expression In Vivo:Correlation With Glucocorticoid-and Developmentally Regulated Expression", Molecular Carcinogenesis 1994 10:189-198
AQ	Merkel et al., "Electrophoretic Analysis of 248 Clinical Breast Cancer Specimens for P-Glycoprotein Overexpression or Gene Amplification", J. Clin. Oncol. 1989 7(8):1129-1136
AR	Nooter et al., "Clinical Relevance of P-Glycoprotein Expression in Haematological Malignancies", Leukemia Research 1994 18(4):233-243

**EXAMINER****DATE CONSIDERED**

<b>Form PTO-1449 Modified</b>		Docket No. <b>DC0270US.NP</b>	Serial No. <b>10/575,577</b>
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>Stanton et al.</b>	
U.S. Department of Commerce		Filing Date <b>Not Yet Assigned</b>	Group <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	AS	Roninson, Igor B., "The Role of the <i>MDR1</i> (P-Glycoprotein) Gene in Multidrug Resistance <i>In Vitro</i> and <i>In Vivo</i> ", Biochemical Pharmacology 1992 43(1):95-102	
	AT	Schneider et al., "P-Glycoprotein expression in treated and untreated human breast cancer", Br. J. Cancer 1989 60:815-818	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b> List of Patents and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce	Docket No. DC0270US.NP	Serial No. 10/575,577
	Applicant Stanton et al.	
	Filing Date Not Yet Assigned	Group Not Yet Assigned

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
	BA	US2004/0087527	5-6-04	Day et al.	514	44
	BB	6,329,172	12-11-01	Rhee et al.	435	69.1
	BC	US2003/0064438	4-3-03	Feder et al.	435	69.1

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation YES	NO

EXAMINER	DATE CONSIDERED
----------	-----------------